Milestone Pharmaceuticals Inc. ( MIST) announced that the first European patient has been enrolled in its Phase 3 ReVeRA-301 clinical trial evaluating etripamil nasal spray for atrial fibrillation ...

“This is an exciting day as it represents our first analyst call reporting on our first ever quarter or, more accurately, partial quarter of sales since the commercial launch of CARDAMYST for acute ...

Milestone Pharmaceuticals has enrolled the first Canadian participant in its ongoing multinational Phase III clinical trial, ReVeRA-301, which is evaluating etripamil nasal spray to treat atrial ...

MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...

Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVRMONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), ...

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...

Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights into over 10 ...

Milestone Pharmaceuticals remains a Hold following a disappointing Q1, with revenue and EPS missing expectations, and shares down 31% post-earnings. MIST's CARDAMYST, a newly approved nasal spray for ...

Milestone Pharmaceuticals Inc. announced that the first European patient has been enrolled in ReVeRA-301, its ongoing Phase 3 pivotal trial evaluating etripamil nasal spray for the treatment of atrial ...

Add Yahoo as a preferred source to see more of our stories on Google. Data collected in this trial are supporting a single-study supplemental NDA registration pathway in AFib-RVR. Credit: Orawan ...